Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

BACKGROUND: Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option for CTEPH. METHODS: In this multicentre, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogo, Takeshi, Shimokawahara, Hiroto, Kinoshita, Hideyuki, Sakao, Seiichiro, Abe, Kohtaro, Matoba, Satoaki, Motoki, Hirohiko, Takama, Noriaki, Ako, Junya, Ikeda, Yasuhiro, Joho, Shuji, Maki, Hisataka, Saeki, Takahiro, Sugano, Teruyasu, Tsujino, Ichizo, Yoshioka, Koichiro, Shiota, Naoki, Tanaka, Shinichi, Yamamoto, Chieko, Tanabe, Nobuhiro, Tatsumi, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260121/
https://www.ncbi.nlm.nih.gov/pubmed/34824052
http://dx.doi.org/10.1183/13993003.01694-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260121/
https://www.ncbi.nlm.nih.gov/pubmed/34824052
http://dx.doi.org/10.1183/13993003.01694-2021

Ejemplares similares